Jazz Pharmaceuticals plc — Form 8-K

Jazz Pharmaceuticals agreed to acquire privately-held Actio Biosciences for $820 million upfront payment plus up to $500 million in contingent milestone payments. The acquisition adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy (ultra-rare genetic disease affecting ~2,500 U.S. patients with no approved treatments), which has FDA Fast Track and Orphan Drug designations and is in Phase 1b/2a KYRON registrational trial. Transaction expected to close by Q4 2026; Jazz will also take a minority stake in a new private entity spun from Actio focusing on rare neurological diseases including TRPV4 inhibitor ABS-0871.